论文部分内容阅读
目的探讨晚期及复发转移乳腺癌患者采取长春瑞滨(盖诺)联合希罗达(卡培他滨)治疗的临床效果。方法回顾性分析28例经蒽环类和紫杉类化疗后复发的晚期及复发转移乳腺癌患者的临床资料,皆予以长春瑞滨联合希罗达治疗,对比分析其临床效果及不良反应情况。结果 28例患者经治疗后,临床总有效率为78.57%(22/28);不良反应主要有12例手足综合征、17例白细胞下降、15例恶心呕吐、8例血小板下降、10例血红蛋白下降、15例脱发等。结论晚期及复发转移乳腺癌患者采取长春瑞滨联合希罗达治疗可以取得比较良好的效果,疗效确切,虽然不良反应较多,但皆可耐受,值得借鉴。
Objective To investigate the clinical effect of vinorelbine (Gano) combined with Xeloda (capecitabine) in patients with advanced and recurrent breast cancer. Methods The clinical data of 28 patients with advanced and recurrent breast cancer who relapsed after anthracycline and taxane chemotherapy were retrospectively analyzed. Both of them were treated with vinorelbine and Xeloda, and their clinical effects and adverse reactions were compared. Results The total clinical effective rate was 78.57% (22/28) after treatment in 28 patients. There were 12 cases of hand-foot syndrome, 17 cases of leukopenia, 15 cases of nausea and vomiting, 8 cases of thrombocytopenia and 10 cases of hemoglobin , 15 cases of hair loss and so on. Conclusions The combination of vinorelbine and Xeloda in patients with advanced and recurrent breast cancer can achieve good results. The curative effect is definite. Although there are more side effects, it is tolerable and worth learning from.